Invasive Aspergillosis
Conditions
Interventions
Standard dose group:Intravenous infusion of Caspofungin at a dose of 70 mg on the first day and 50 mg/day thereafter
100 mg group:Intravenous infusion of 100mg/day of Caspofungin
150 mg group:Intravenous infusion of 150mg/day of Caspofungin
200 mg group:Intravenous infusion of 200mg/day of Caspofungin
Sponsors
Jiaozuo People's Hospital
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age>16 years old, with normal weight; Blood disease patients diagnosed with invasive aspergillosis (lung/blood flow); Those who accept the use of Caspofungin for (11 ± 3) days; Individuals receiving single anti-aspergillus treatment with Caspofungin; Female patients of childbearing age must test negative for pregnancy at the beginning of the study, and appropriate contraceptive measures must be taken throughout the entire study process.
Exclusion criteria
Exclusion criteria: Hypoproteinemia; Those with severe heart, brain, or other important organ dysfunction; Severe diseases or breakthrough fungal infections that involve multiple organs; Patients who are unable to tolerate the adverse reactions of caspofungin or cannot continue to use the drug for anti infection treatment due to their own disease progression; Individuals who are known or suspected to be allergic to or have serious adverse reactions to the studied carbaprofen; Those who are ineffective in treating the infected pathogenic microorganisms (such as Pneumocystis carinii and Mucor) with Caspofungin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate efficacy;; | — |
Secondary
| Measure | Time frame |
|---|---|
| safety; | — |
Countries
China
Contacts
Public ContactSong Qinglin
Jiaozuo People's Hospital affiliated to Xinxiang Medical University
Outcome results
None listed